Condition: Myotonic Dystrophy · Sponsor: Lupin Ltd.
A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients with Myotonic Dystrophy Type 1 and Type 2 (HERCULES study)
This description comes directly from the study's public registry record.
Nikki Adetoro · 1 443-447-4534 · nikkiadetoro@lupin.com
Always discuss trial participation with your own doctor first.
| Laboratory for Muscle Diseases and Neuropathies | Leuven, Belgium | Recruiting |
| Aarhus University Hospital | Aarhus, Denmark | Recruiting |
| Ludug-Maximilians University | München, Germany | Recruiting |
| Azienda Ospedaliera Universitaria Policlinico Tor Vergata | Rome, Italy | Recruiting |
| University Hospital of Madrid | Madrid, Spain | Recruiting |
| Saint George's University Hospitals NHS Foundation Trust | London, United Kingdom | Recruiting |
| University College Hospital | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06523400